Loading…
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
Treatment efficacy and costs of anti-VEGF drugs have not been studied in clinical routine. To compare treatment costs and clinical outcomes of the medications when adjusting for patients' characteristics and clinical status. Comparative study. The largest public ophthalmologic clinic in Switzer...
Saved in:
| Published in: | PloS one 2015-08, Vol.10 (8), p.e0135050-e0135050 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103 |
| container_end_page | e0135050 |
| container_issue | 8 |
| container_start_page | e0135050 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Schmid, Martin K Reich, Oliver Faes, Livia Boehni, Sophie C Bittner, Mario Howell, Jeremy P Thiel, Michael A Signorell, Andri Bachmann, Lucas M |
| description | Treatment efficacy and costs of anti-VEGF drugs have not been studied in clinical routine.
To compare treatment costs and clinical outcomes of the medications when adjusting for patients' characteristics and clinical status.
Comparative study.
The largest public ophthalmologic clinic in Switzerland.
Health care claims data of patients with age-related macular degeneration, diabetic macula edema and retinal vein occlusion were matched to clinical and outcome data.
Patients' underlying condition, gender, age, visual acuity and retinal thickness at baseline and after completing the loading phase, the total number of injections per treatment, the visual outcome and vital status was secured.
We included 315 patients (19595 claims) with a follow-up time of 1 to 99 months (mean 32.7, SD 25.8) covering the years 2006-2014. Mean age was 78 years (SD 9.3) and 200 (63.5%) were female. At baseline, the mean number of letters was 55.6 (SD 16.3) and the central retinal thickness was 400.1 μm (SD 110.1). Patients received a mean number of 15.1 injections (SD 13.7; range 1 to 85). Compared to AMD, adjusted cost per month were significantly higher (+2174.88 CHF, 95%CI: 1094.50-3255.27; p |
| doi_str_mv | 10.1371/journal.pone.0135050 |
| format | article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2044551602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A432650487</galeid><doaj_id>oai_doaj_org_article_1a02d32817cf4393aaab1af1da72ac25</doaj_id><sourcerecordid>A432650487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103</originalsourceid><addsrcrecordid>eNqNk1uLEzEUxwdR3HX1G4gOCKIPrbnNJPMilOKlUFio676GM2nSpsxMuklG1E9vup1dOrKg5CHhnN_5JzmXLHuJ0RRTjj_sXO87aKZ71-kpwrRABXqUneOKkklJEH18cj7LnoWwQ6igoiyfZmekJAyLgpxn13PX7sHb4Lrcmfyyj8q1OuTQrfO5CzEcrCvobG1_9y3Ut46ZaWytvdL7mF95DbHVXcxtl680NJOlNfp59sRAE_SLYb_Ivn_-dDX_OlleflnMZ8uJ4qSIE1JrXmkwphB1TQUYViItBKmp1qLknFU1Y5gLgksKwhgNAoQyBAtWIYMRvcheH3X3jQtySEmQBDFWFLhEJBGLI7F2sJN7b1vwv6QDK28Nzm8k-GhVoyUGRNaUCMyVYbSiAFBjMHgNnIAiRdL6ONzW161eq_RrD81IdOzp7FZu3A_JCsI4pkng3SDg3U2vQ5StDUo3DXTa9UFigVKBuGDlv1GOCKpwWR2e9eYv9OFEDNQG0l9tZ1x6ojqIyhmjpCwQEzxR0weotNa6tSq1mrHJPgp4PwpITNQ_4wb6EOTi2-r_2cvrMfv2hN2mxorb4Jo-WteFMciOoPIuBK_NfT0wkodJucuGPEyKHCYlhb06reV90N1o0D8WYQxd</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2044551602</pqid></control><display><type>article</type><title>Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Schmid, Martin K ; Reich, Oliver ; Faes, Livia ; Boehni, Sophie C ; Bittner, Mario ; Howell, Jeremy P ; Thiel, Michael A ; Signorell, Andri ; Bachmann, Lucas M</creator><contributor>Abe, Toshiaki</contributor><creatorcontrib>Schmid, Martin K ; Reich, Oliver ; Faes, Livia ; Boehni, Sophie C ; Bittner, Mario ; Howell, Jeremy P ; Thiel, Michael A ; Signorell, Andri ; Bachmann, Lucas M ; Abe, Toshiaki</creatorcontrib><description>Treatment efficacy and costs of anti-VEGF drugs have not been studied in clinical routine.
To compare treatment costs and clinical outcomes of the medications when adjusting for patients' characteristics and clinical status.
Comparative study.
The largest public ophthalmologic clinic in Switzerland.
Health care claims data of patients with age-related macular degeneration, diabetic macula edema and retinal vein occlusion were matched to clinical and outcome data.
Patients' underlying condition, gender, age, visual acuity and retinal thickness at baseline and after completing the loading phase, the total number of injections per treatment, the visual outcome and vital status was secured.
We included 315 patients (19595 claims) with a follow-up time of 1 to 99 months (mean 32.7, SD 25.8) covering the years 2006-2014. Mean age was 78 years (SD 9.3) and 200 (63.5%) were female. At baseline, the mean number of letters was 55.6 (SD 16.3) and the central retinal thickness was 400.1 μm (SD 110.1). Patients received a mean number of 15.1 injections (SD 13.7; range 1 to 85). Compared to AMD, adjusted cost per month were significantly higher (+2174.88 CHF, 95%CI: 1094.50-3255.27; p<0.001) for patients with DME, while cost per month for RVO were slightly but not significantly higher. (+284.71 CHF, 95% CI: -866.73-1436.15; p = 0.627).
Patients with DME are almost twice as expensive as AMD and RVO patients. Cost excess occurs with non-ophthalmologic interventions. The currently licensed anti-VEGF medications did not differ in costs, injection frequency and clinical outcomes. Linking health care claims to clinical data is a useful tool to examine routine clinical care.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0135050</identifier><identifier>PMID: 26241852</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acuity ; Aflibercept ; Age ; Age related diseases ; Aged ; Ambulatory Care Facilities - statistics & numerical data ; Comparative analysis ; Comparative studies ; Costs ; Costs and Cost Analysis ; Diabetes mellitus ; Diabetic Retinopathy - drug therapy ; Diabetic Retinopathy - economics ; Drug therapy ; Economic aspects ; Edema ; Ethics ; Female ; Health aspects ; Health care ; Health care costs ; Health Care Costs - statistics & numerical data ; Health care expenditures ; Health sciences ; Hospitals ; Humans ; Immunotherapy ; Insurance Claim Review ; Macular degeneration ; Macular Degeneration - drug therapy ; Macular Degeneration - economics ; Macular Edema - drug therapy ; Macular Edema - economics ; Male ; Monoclonal antibodies ; Occlusion ; Patient outcomes ; Patients ; Performance evaluation ; Ranibizumab ; Ranibizumab - economics ; Ranibizumab - therapeutic use ; Receptors, Vascular Endothelial Growth Factor - economics ; Receptors, Vascular Endothelial Growth Factor - therapeutic use ; Recombinant Fusion Proteins - economics ; Recombinant Fusion Proteins - therapeutic use ; Retina ; Retinal Vein Occlusion - drug therapy ; Retinal Vein Occlusion - economics ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity</subject><ispartof>PloS one, 2015-08, Vol.10 (8), p.e0135050-e0135050</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Schmid et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Schmid et al 2015 Schmid et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103</citedby><cites>FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2044551602/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2044551602?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26241852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Abe, Toshiaki</contributor><creatorcontrib>Schmid, Martin K</creatorcontrib><creatorcontrib>Reich, Oliver</creatorcontrib><creatorcontrib>Faes, Livia</creatorcontrib><creatorcontrib>Boehni, Sophie C</creatorcontrib><creatorcontrib>Bittner, Mario</creatorcontrib><creatorcontrib>Howell, Jeremy P</creatorcontrib><creatorcontrib>Thiel, Michael A</creatorcontrib><creatorcontrib>Signorell, Andri</creatorcontrib><creatorcontrib>Bachmann, Lucas M</creatorcontrib><title>Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Treatment efficacy and costs of anti-VEGF drugs have not been studied in clinical routine.
To compare treatment costs and clinical outcomes of the medications when adjusting for patients' characteristics and clinical status.
Comparative study.
The largest public ophthalmologic clinic in Switzerland.
Health care claims data of patients with age-related macular degeneration, diabetic macula edema and retinal vein occlusion were matched to clinical and outcome data.
Patients' underlying condition, gender, age, visual acuity and retinal thickness at baseline and after completing the loading phase, the total number of injections per treatment, the visual outcome and vital status was secured.
We included 315 patients (19595 claims) with a follow-up time of 1 to 99 months (mean 32.7, SD 25.8) covering the years 2006-2014. Mean age was 78 years (SD 9.3) and 200 (63.5%) were female. At baseline, the mean number of letters was 55.6 (SD 16.3) and the central retinal thickness was 400.1 μm (SD 110.1). Patients received a mean number of 15.1 injections (SD 13.7; range 1 to 85). Compared to AMD, adjusted cost per month were significantly higher (+2174.88 CHF, 95%CI: 1094.50-3255.27; p<0.001) for patients with DME, while cost per month for RVO were slightly but not significantly higher. (+284.71 CHF, 95% CI: -866.73-1436.15; p = 0.627).
Patients with DME are almost twice as expensive as AMD and RVO patients. Cost excess occurs with non-ophthalmologic interventions. The currently licensed anti-VEGF medications did not differ in costs, injection frequency and clinical outcomes. Linking health care claims to clinical data is a useful tool to examine routine clinical care.</description><subject>Acuity</subject><subject>Aflibercept</subject><subject>Age</subject><subject>Age related diseases</subject><subject>Aged</subject><subject>Ambulatory Care Facilities - statistics & numerical data</subject><subject>Comparative analysis</subject><subject>Comparative studies</subject><subject>Costs</subject><subject>Costs and Cost Analysis</subject><subject>Diabetes mellitus</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Diabetic Retinopathy - economics</subject><subject>Drug therapy</subject><subject>Economic aspects</subject><subject>Edema</subject><subject>Ethics</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health care</subject><subject>Health care costs</subject><subject>Health Care Costs - statistics & numerical data</subject><subject>Health care expenditures</subject><subject>Health sciences</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Insurance Claim Review</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - economics</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - economics</subject><subject>Male</subject><subject>Monoclonal antibodies</subject><subject>Occlusion</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Performance evaluation</subject><subject>Ranibizumab</subject><subject>Ranibizumab - economics</subject><subject>Ranibizumab - therapeutic use</subject><subject>Receptors, Vascular Endothelial Growth Factor - economics</subject><subject>Receptors, Vascular Endothelial Growth Factor - therapeutic use</subject><subject>Recombinant Fusion Proteins - economics</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Retina</subject><subject>Retinal Vein Occlusion - drug therapy</subject><subject>Retinal Vein Occlusion - economics</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1uLEzEUxwdR3HX1G4gOCKIPrbnNJPMilOKlUFio676GM2nSpsxMuklG1E9vup1dOrKg5CHhnN_5JzmXLHuJ0RRTjj_sXO87aKZ71-kpwrRABXqUneOKkklJEH18cj7LnoWwQ6igoiyfZmekJAyLgpxn13PX7sHb4Lrcmfyyj8q1OuTQrfO5CzEcrCvobG1_9y3Ut46ZaWytvdL7mF95DbHVXcxtl680NJOlNfp59sRAE_SLYb_Ivn_-dDX_OlleflnMZ8uJ4qSIE1JrXmkwphB1TQUYViItBKmp1qLknFU1Y5gLgksKwhgNAoQyBAtWIYMRvcheH3X3jQtySEmQBDFWFLhEJBGLI7F2sJN7b1vwv6QDK28Nzm8k-GhVoyUGRNaUCMyVYbSiAFBjMHgNnIAiRdL6ONzW161eq_RrD81IdOzp7FZu3A_JCsI4pkng3SDg3U2vQ5StDUo3DXTa9UFigVKBuGDlv1GOCKpwWR2e9eYv9OFEDNQG0l9tZ1x6ojqIyhmjpCwQEzxR0weotNa6tSq1mrHJPgp4PwpITNQ_4wb6EOTi2-r_2cvrMfv2hN2mxorb4Jo-WteFMciOoPIuBK_NfT0wkodJucuGPEyKHCYlhb06reV90N1o0D8WYQxd</recordid><startdate>20150804</startdate><enddate>20150804</enddate><creator>Schmid, Martin K</creator><creator>Reich, Oliver</creator><creator>Faes, Livia</creator><creator>Boehni, Sophie C</creator><creator>Bittner, Mario</creator><creator>Howell, Jeremy P</creator><creator>Thiel, Michael A</creator><creator>Signorell, Andri</creator><creator>Bachmann, Lucas M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150804</creationdate><title>Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life</title><author>Schmid, Martin K ; Reich, Oliver ; Faes, Livia ; Boehni, Sophie C ; Bittner, Mario ; Howell, Jeremy P ; Thiel, Michael A ; Signorell, Andri ; Bachmann, Lucas M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acuity</topic><topic>Aflibercept</topic><topic>Age</topic><topic>Age related diseases</topic><topic>Aged</topic><topic>Ambulatory Care Facilities - statistics & numerical data</topic><topic>Comparative analysis</topic><topic>Comparative studies</topic><topic>Costs</topic><topic>Costs and Cost Analysis</topic><topic>Diabetes mellitus</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Diabetic Retinopathy - economics</topic><topic>Drug therapy</topic><topic>Economic aspects</topic><topic>Edema</topic><topic>Ethics</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health care</topic><topic>Health care costs</topic><topic>Health Care Costs - statistics & numerical data</topic><topic>Health care expenditures</topic><topic>Health sciences</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Insurance Claim Review</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - economics</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - economics</topic><topic>Male</topic><topic>Monoclonal antibodies</topic><topic>Occlusion</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Performance evaluation</topic><topic>Ranibizumab</topic><topic>Ranibizumab - economics</topic><topic>Ranibizumab - therapeutic use</topic><topic>Receptors, Vascular Endothelial Growth Factor - economics</topic><topic>Receptors, Vascular Endothelial Growth Factor - therapeutic use</topic><topic>Recombinant Fusion Proteins - economics</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Retina</topic><topic>Retinal Vein Occlusion - drug therapy</topic><topic>Retinal Vein Occlusion - economics</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmid, Martin K</creatorcontrib><creatorcontrib>Reich, Oliver</creatorcontrib><creatorcontrib>Faes, Livia</creatorcontrib><creatorcontrib>Boehni, Sophie C</creatorcontrib><creatorcontrib>Bittner, Mario</creatorcontrib><creatorcontrib>Howell, Jeremy P</creatorcontrib><creatorcontrib>Thiel, Michael A</creatorcontrib><creatorcontrib>Signorell, Andri</creatorcontrib><creatorcontrib>Bachmann, Lucas M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmid, Martin K</au><au>Reich, Oliver</au><au>Faes, Livia</au><au>Boehni, Sophie C</au><au>Bittner, Mario</au><au>Howell, Jeremy P</au><au>Thiel, Michael A</au><au>Signorell, Andri</au><au>Bachmann, Lucas M</au><au>Abe, Toshiaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-08-04</date><risdate>2015</risdate><volume>10</volume><issue>8</issue><spage>e0135050</spage><epage>e0135050</epage><pages>e0135050-e0135050</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Treatment efficacy and costs of anti-VEGF drugs have not been studied in clinical routine.
To compare treatment costs and clinical outcomes of the medications when adjusting for patients' characteristics and clinical status.
Comparative study.
The largest public ophthalmologic clinic in Switzerland.
Health care claims data of patients with age-related macular degeneration, diabetic macula edema and retinal vein occlusion were matched to clinical and outcome data.
Patients' underlying condition, gender, age, visual acuity and retinal thickness at baseline and after completing the loading phase, the total number of injections per treatment, the visual outcome and vital status was secured.
We included 315 patients (19595 claims) with a follow-up time of 1 to 99 months (mean 32.7, SD 25.8) covering the years 2006-2014. Mean age was 78 years (SD 9.3) and 200 (63.5%) were female. At baseline, the mean number of letters was 55.6 (SD 16.3) and the central retinal thickness was 400.1 μm (SD 110.1). Patients received a mean number of 15.1 injections (SD 13.7; range 1 to 85). Compared to AMD, adjusted cost per month were significantly higher (+2174.88 CHF, 95%CI: 1094.50-3255.27; p<0.001) for patients with DME, while cost per month for RVO were slightly but not significantly higher. (+284.71 CHF, 95% CI: -866.73-1436.15; p = 0.627).
Patients with DME are almost twice as expensive as AMD and RVO patients. Cost excess occurs with non-ophthalmologic interventions. The currently licensed anti-VEGF medications did not differ in costs, injection frequency and clinical outcomes. Linking health care claims to clinical data is a useful tool to examine routine clinical care.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26241852</pmid><doi>10.1371/journal.pone.0135050</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-08, Vol.10 (8), p.e0135050-e0135050 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2044551602 |
| source | Open Access: PubMed Central; Publicly Available Content Database |
| subjects | Acuity Aflibercept Age Age related diseases Aged Ambulatory Care Facilities - statistics & numerical data Comparative analysis Comparative studies Costs Costs and Cost Analysis Diabetes mellitus Diabetic Retinopathy - drug therapy Diabetic Retinopathy - economics Drug therapy Economic aspects Edema Ethics Female Health aspects Health care Health care costs Health Care Costs - statistics & numerical data Health care expenditures Health sciences Hospitals Humans Immunotherapy Insurance Claim Review Macular degeneration Macular Degeneration - drug therapy Macular Degeneration - economics Macular Edema - drug therapy Macular Edema - economics Male Monoclonal antibodies Occlusion Patient outcomes Patients Performance evaluation Ranibizumab Ranibizumab - economics Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - economics Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - economics Recombinant Fusion Proteins - therapeutic use Retina Retinal Vein Occlusion - drug therapy Retinal Vein Occlusion - economics Tomography, Optical Coherence Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity |
| title | Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A35%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Outcomes%20and%20Costs%20of%20Ranibizumab%20and%20Aflibercept%20Treatment%20in%20Real-Life&rft.jtitle=PloS%20one&rft.au=Schmid,%20Martin%20K&rft.date=2015-08-04&rft.volume=10&rft.issue=8&rft.spage=e0135050&rft.epage=e0135050&rft.pages=e0135050-e0135050&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0135050&rft_dat=%3Cgale_plos_%3EA432650487%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c725t-2be79eaff58bb38af460e882b3ee867749b441782163a8ffea8a8cf218490f103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2044551602&rft_id=info:pmid/26241852&rft_galeid=A432650487&rfr_iscdi=true |